Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection

Détails

ID Serval
serval:BIB_4AC0838E2602
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Périodique
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Auteur(s)
Widmer  N., Beguin  A., Rochat  B., Buclin  T., Kovacsovics  T., Duchosal  M. A., Leyvraz  S., Rosselet  A., Biollaz  J., Decosterd  L. A.
ISSN
1570-0232 (Print)
Statut éditorial
Publié
Date de publication
04/2004
Peer-reviewed
Oui
Volume
803
Numéro
2
Pages
285-292
Langue
anglais
Notes
Journal Article --- Old month value: Apr 25
Résumé
A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection. Plasma (750 microl), with clozapine added as internal standard, is diluted 3 + 1 with water and subjected to a solid-phase extraction on a C18 cartridge. After matrix components elimination with 2000 microl of water (in two aliquots of 1000 microl), imatinib is eluted with 3 x 500 microl MeOH. The resulting eluate is evaporated under nitrogen at room temperature and is reconstituted in 180 microl 50% methanol. A 50 microl volume is injected onto a Nucleosil 100-5 microm C18 AB column. Imatinib is analyzed using a gradient elution program with solvent mixture constituted of methanol and water containing both 0.05% ammonium acetate. Imatinib is detected by UV at 261 nm. The calibration curves are linear between 0.1 and 10 microg/ml. The limit of quantification and detection are 0.05 and 0.01 microg/ml, respectively. The mean absolute recovery of imatinib is 96%. The method is precise with mean inter-day CVs within 1.1-2.4%, and accurate (range of inter-day deviations -0.6 to +0.7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.
Mots-clé
Antineoplastic Agents/*blood Chromatography, High Pressure Liquid/*methods Humans Piperazines/*blood Pyrimidines/*blood Reproducibility of Results Sensitivity and Specificity Spectrophotometry, Ultraviolet/*methods
Pubmed
Web of science
Création de la notice
28/01/2008 8:32
Dernière modification de la notice
20/08/2019 13:58
Données d'usage